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Beta-thalassemia is considered one of the most common
genetic disorders which mass migration is introducing to
countries worldwide and challenging them with its man-
agement. Advanced and improved medical care has allowed
us to prolong the lives of thalassemia patients, simultane-
ously uncovering novel complications and outlining new
challenges. We herein present in this special issue of Anemia
some of the most cutting-edge research outcomes pertaining
to the latest complications and the novel treatment strategies
in iron-chelation therapy. We also study the eﬀects of these
interventions on the quality of life of patients. It is studies like
these that serve as the basis of evidence-based medicine and
guide clinicians through their process of decision making.
One article of this special issue addresses the new method
of using transactional Doppler ultrasonography for measur-
ing intracranial blood flow velocity in patients with beta-
thalassemia intermedia. This study shows higher blood flow
velocity in these patients compared to the control group,
which may point to a higher risk of ischemic events in the
future.
Another paper discusses that thalassemic DNA-con-
taining red blood cells are under oxidative stress, which
induces externalization of phosphatidylserine. This mech-
anism is involved in the removal of these cells from the
circulation by the spleen, similar to that of the removal of
senescent red blood cells.
This special issue also includes a paper explaining the
pathophysiology of bone modifications in beta-thalassemia.
Imbalance in mineral turnover resulting in abnormal regula-
tion of bone metabolism may be related to hormonal and
genetic factors, iron overload, and iron chelation therapy.
These factors and their contribution are addressed.
Moreover, a review article that addresses the mechanism
of tissue damage arising from iron overload in patients with
β-thalassemia major is presented. It is the result of oxidative
stress from free radical production, altered antioxidant
enzymes, and its interaction with other essential trace ele-
ment levels.
The last paper presented is a study comparing the quality
of life in patients with β-thalassemia major and myelo-
dysplastic syndrome with iron-overload treated either with
deferasirox or deferoxamine injections. The results show
that deferasirox can improve health-related quality of life
treatment satisfaction and adherence compared to subcuta-
neous deferoxamine injection. This issue is crucial and often
neglected in the long-term treatment of patients with iron
overload.
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